Subacute Hemolysis in Sickle Cell Mice Causes Priapism Secondary to NO Imbalance and PDE5 Dysregulation.

INTRODUCTION Recent research suggests that priapism in sickle cell disease (SCD) is due to dysregulation of penile erection homeostasis including alteration of nitric oxide synthase (NOS) and phosphodiesterase type 5 (PDE5) activities by excessive levels of reactive oxygen species (ROS) released during hemolysis. It is unknown if subacute exposure to hemolysis is sufficient or if chronic reconditioning of erectile tissues is required for perturbation of homeostatic pathways and whether PDE5 inhibitor (PDE5I) treatment can restore erectile homeostasis in the subacute setting. AIMS The aim of this study was to investigate the effects of subacute hemolysis (3-month exposure) on priapism and NO pathway regulation. METHODS Mice underwent bone marrow transplantation with either SCD (BM-SS) or wild-type (WT) bone marrow. BM-SS mice were treated with sildenafil 100 mg/kg/day. We measured intracavernous pressure (ICP) measurements with or without cavernous nerve stimulation following bone marrow transplantation to assess for priapism. MAIN OUTCOME MEASURES ICP and frequency of erections were assessed. Penile tissues were analyzed for NOS, protein kinase G (PKG), PDE5, and ROS activities. RESULTS BM-SS mice demonstrated a priapism phenotype. PDE5I treatment reduced the frequency of erections in BM-SS mice (1.7 ± 1.1 vs. 5.5 ± 2.8 erections per hour, P < 0.05). Penile tissues from BM-SS mice demonstrated decreased NOS, PKG, PDE5 and elevated ROS activities compared with that of control mice. PDE5I treatment increased NOS (11.6 ± 1.3% vs. 7.8 ± 2.3%, P < 0.05) and PDE5 (76.3 ± 9.8% vs. 52.3 ± 11.1%, P < 0.05) activities and decreased ROS activity (137.8 ± 12.1% vs. 199.1 ± 11.3%, P < 0.05) compared with non-PDE5I treated BM-SS mice. PKG activity was increased beyond control levels with PDE5I treatment (158.4 ± 10.3%, P < 0.05). CONCLUSION Short-term hemolysis is sufficient to establish a priapism phenotype and results in loss of erectile function. PDE5I treatment ameliorates priapism, in part, because of restored NO balance with decreased ROS generation and increased PDE5 activity.

[1]  A. Burnett,et al.  Caspase-3 dependent nitrergic neuronal apoptosis following cavernous nerve injury is mediated via RhoA and ROCK activation in major pelvic ganglion , 2016, Scientific Reports.

[2]  K. Davies,et al.  Opiorphin is a master regulator of the hypoxic response in corporal smooth muscle cells , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  A. Burnett,et al.  Randomized controlled trial of sildenafil for preventing recurrent ischemic priapism in sickle cell disease. , 2014, The American journal of medicine.

[4]  M. Blackburn,et al.  Excess adenosine A2B receptor signaling contributes to priapism through HIF‐1α mediated reduction of PDE5 gene expression , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  A. Burnett,et al.  Sildenafil Citrate-Restored eNOS and PDE5 Regulation in Sickle Cell Mouse Penis Prevents Priapism Via Control of Oxidative/Nitrosative Stress , 2013, PloS one.

[6]  C. Stief,et al.  Inhibition of Rho-kinase improves erectile function, increases nitric oxide signaling and decreases penile apoptosis in a rat model of cavernous nerve injury. , 2013, The Journal of urology.

[7]  A. Burnett,et al.  Post-translational inactivation of endothelial nitric oxide synthase in the transgenic sickle cell mouse penis. , 2011, The journal of sexual medicine.

[8]  M. Gladwin,et al.  Establishment of a transgenic sickle-cell mouse model to study the pathophysiology of priapism. , 2009, The journal of sexual medicine.

[9]  K. Davies,et al.  The mechanism of opiorphin-induced experimental priapism in rats involves activation of the polyamine synthetic pathway. , 2009, American journal of physiology. Cell physiology.

[10]  F. Costa,et al.  Increased cavernosal relaxations in sickle cell mice priapism are associated with alterations in the NO-cGMP signaling pathway. , 2009, The journal of sexual medicine.

[11]  Tiejuan Mi,et al.  Excess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signaling. , 2008, The Journal of clinical investigation.

[12]  A. Burnett,et al.  Endothelial nitric oxide synthase keeps erection regulatory function balance in the penis. , 2007, European urology.

[13]  M. Gladwin,et al.  Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. , 2006, Blood.

[14]  W. Baldwin,et al.  The production of red blood cell alloantibodies in mice transfused with blood from transgenic Fyb‐expressing mice , 2006, Transfusion.

[15]  T. Bivalacqua,et al.  Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism. , 2006, Urology.

[16]  C. Bodian,et al.  Pathology of Berkeley sickle cell mice: similarities and differences with human sickle cell disease. , 2006, Blood.

[17]  L. Farrer,et al.  Hemolysis-associated Priapism in Sickle Cell Disease , 2005 .

[18]  Z. Rogers.  Priapism in sickle cell disease. , 2005, Hematology/oncology clinics of North America.

[19]  Stanley L Hazen,et al.  Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. , 2005, JAMA.

[20]  D. Granger,et al.  Endothelial cell NADPH oxidase mediates the cerebral microvascular dysfunction in sickle cell transgenic mice , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  M. Gladwin,et al.  The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. , 2005, JAMA.

[22]  D. Kass,et al.  Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[23]  A. Burnett.  Priapism pathophysiology: clues to prevention , 2003, International Journal of Impotence Research.

[24]  C. B. Alexander,et al.  Nitric Oxide-dependent Generation of Reactive Species in Sickle Cell Disease , 2003, The Journal of Biological Chemistry.

[25]  J. Liao.  Blood feud: Keeping hemoglobin from nixing NO , 2002, Nature Medicine.

[26]  A. Adeyoju,et al.  Priapism in sickle‐cell disease; incidence, risk factors and complications – an international multicentre study , 2002, BJU international.

[27]  M. Gladwin,et al.  Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[28]  T. Lue,et al.  Identification and regulation of human PDE5A gene promoter. , 2001, Biochemical and biophysical research communications.

[29]  E. Rubin,et al.  Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. , 1997, Science.

[30]  A. Burnett,et al.  New insights into the pathophysiology of sickle cell disease-associated priapism. , 2012, The journal of sexual medicine.

[31]  T. Bivalacqua,et al.  Priapism: pathogenesis, epidemiology, and management. , 2010, The journal of sexual medicine.

[32]  M. Gladwin,et al.  Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. , 2007, Blood reviews.

[33]  C. B. Alexander,et al.  Nitric oxide-dependent generation of reactive species in sickle cell disease. Actin tyrosine induces defective cytoskeletal polymerization. , 2003, The Journal of biological chemistry.

[34]  M. Gladwin,et al.  Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease , 2002, Nature Medicine.